Category: 386704-04-7

On March 31, 2016, Cai, Jiaqiang; Colandrea, Vincent; Crespo, Alejandro; Debenham, John; Du, Xiaoxing; Guiadeen, Deodialsingh; Liu, Ping; Liu, Rongqiang; Madsen-Duggan, Cristina B.; McCoy, Joshua G.; Quan, Weiguo; Sinz, Christopher; Wang, Liping published a patent.Safety of (6-(Trifluoromethyl)pyridin-3-yl)methanol The title of the patent was Quinolinecarboxamidoacetic acids and related compounds as inhibitors of HIF prolyl hydroxylase and their preparation. And the patent contained the following:

The invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier. Compounds of formula I wherein W and Z are independently CH2 and NH and derivatives; X and Y are independently CH2, O, CO and NH and derivatives; provided that when W and Z are CH2, then WZ may be taken together with another carbon to form a bridge; R1 is H, C1-4 alkyl, (un)substituted C3-8 cycloalkyl, (un)substituted aryl, (un)substituted heterocyclyl, etc.; R2 is H and Me; R3 and R4 are independently H, OH and (un)substituted C1-4 alkyl; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their HIF prolyl hydroxylase inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value of 19.2 nM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Safety of (6-(Trifluoromethyl)pyridin-3-yl)methanol

The Article related to quinolinecarboxamidoacetic acid preparation hif prolyl hydroxylase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Safety of (6-(Trifluoromethyl)pyridin-3-yl)methanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On January 6, 2011, Guzzo, Peter R.; Surman, Matthew David; Henderson, Alan John; Jiang, May Xiaowu published a patent.Name: (6-(Trifluoromethyl)pyridin-3-yl)methanol The title of the patent was Preparation of azinone-substituted azapolycycles as MCH-1 receptor antagonists and use in the treatment of diseases. And the patent contained the following:

Title compounds I [R1 = H, (un)substituted alkyl, alkenyl, alkynyl, etc; R2 and R4 independently = H, CONH2 and derivatives, (un)substituted alkyl, aryl, etc.; R2 and R3 or R3 and R4 taken together to form an (un)substituted 3- to 7-membered heterocycle; at least one of R2 and R3 or R3 and R4 taken together to form an (un)substituted 3- to 7-membered heterocycle; each R5 independently = H, halo, NH2 and derivatives, (un)substituted alkyl, aryl, etc.; R6 = H, halo, (un)substituted aryl, heteroaryl, etc.; A = (CH2)m; B = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; D = (CH2)n; L = (CH2)pO, (CH2)p, CH=CH, or bond; X = CR12, C(R12)2, N, or NR12; Y = CR12, C, or N; Z = CH, C, or N; R12 = H, halo, NH2 and derivatives, (un)substituted alkyl, aryl, etc.; m and n = 0 or 1, wherein m + n = 1; p = 1 to 4; q = 0 to 3; dash bond represents an optional double bound], and their pharmaceutically acceptable salts, oxides, solvates, or prodrugs, are prepared and disclosed as MCH-1 receptor antagonists and useful in the treatment of obesity, anxiety, depression, non-alc. fatty liver disease, and psychiatric disorders. Thus, e.g., II·HCl was prepared by acylation of 2-(6-bromo-1-methyl-1H-indol-3-yl)ethanamine with 4-bromobutyryl chloride followed by intramol. cyclization, intramol. reductive N-alkylation, amination with 4-(benzyloxy)pyridin-2(1H)-one, and addition of hydrochloric acid. Select I were evaluated for their MCH-1 antagonistic activity, e.g., II·HCl demonstrated a Ki value of 14.9 nM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Name: (6-(Trifluoromethyl)pyridin-3-yl)methanol

The Article related to azinone azapolycycle preparation mch receptor antagonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Name: (6-(Trifluoromethyl)pyridin-3-yl)methanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On July 3, 2008, Ibrahim, Prabha N.; Bremer, Ryan; Zhang, Chao; Zhang, Jiazhong; Hirth, Klaus-Peter; Wu, Guoxian; Zhu, Hongyao published a patent.Application of 386704-04-7 The title of the patent was Pyrrolo[2,3-b]pyridine compounds and methods for kinase modulation, preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

Compounds of formula I, which are active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. Compounds of formula I wherein n is 0, 1, 2 and 3; Z2 is N and CR12; Z6 is CR16; L4 is (CR10R11)p-X-(CR10R11)q; X is O, S, NH and derivatives, CO, CS, SO, SO2, CONH and derivatives, CSNH and derivatives, NHCO and derivatives, etc.; p and q are independently 0, 1 and 2, provides that at least one of p and 1 is 0; R4, R5, R6, R11, R15, R16 and R60 is H, halo, (un)substituted lower alkyl, (un)substituted lower alkenyl, (un)substituted lower alkynyl, (un)substituted (hetero)cycloalkyl, (un)substituted (hetero)aryl, etc.; R61 is H and lower (fluoro)alkyl; A is O, S, CH2, CHOH, CHNH2, CF2, CHF, NH and derivatives, CO, CS, SO, SO2, etc.; R10 and R11 and independently H, F and (un)substituted lower alkyl; R17 is H, halo, (un)substituted lower alkyl, OH and derivatives; and their salts, prodrugs, tautomers and isomers thereof, are claimed. Example compound II was prepared by benzylation of 4-hydroxy-3-methoxybenzaldehyde with 4-chlorobenzyl bromide; the resulting 4-(4-chlorobenzyloxy)-3-methoxybenzaldehyde underwent addition of 7-azaindole to give 3-((4-(4-chlorobenzyloxy)-3-methoxyphenyl)(methoxy)methyl)-1H-pyrrolo[2,3-b]pyridine, which underwent demethoxylation to give compound II. All the invention compounds were evaluated for their protein kinase modulatory activity (some data given). The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Application of 386704-04-7

The Article related to pyrrolopyridine preparation protein kinase modulator treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Application of 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On July 3, 2008, Ibrahim, Prabha N.; Bremer, Ryan; Zhang, Chao; Zhang, Jiazhong; Hirth, Klaus-Peter; Wu, Guoxian; Zhu, Hongyao published a patent.Recommanded Product: 386704-04-7 The title of the patent was Pyrrolo[2,3-]pyridine compounds and methods for kinase modulation, preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

Compounds of formula I, which are active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. Compounds of formula I wherein A1 is O, CR40R41, CO and NH and derivatives; Z2 is N and CR56; Z6 is N and CR52; L3 is NH and derivatives, S, O, CONH and derivatives, NHCO and derivatives, etc.; R40, R41, R52 and R56 are independently H, F, lower (fluoro)alkyl, lower (fluoro)alkoxy, lower (fluoro)alkylthio, etc.; R61 is H, and lower (fluoro)alkyl; R100 and R101 are independently H, OH, NH2, CN, CO2H, NO2, SO2NH2, CONH2, etc.; R53 and R55 are independently H, halo, (un)substituted lower alkyl and (un)substituted lower alkoxy; n is 0, 1, 2 and 3; and their salts, prodrugs, tautomers, and isomers thereof, are claimed. Example compound II was prepared by addition of 7-azaindole to 4-(4-chlorobenzyloxy)-3-fluorobenzaldehyde; the resulting [4-(4-chlorobenzyloxy)-3-fluorophenyl]-(1H-pyrrolo[2,3-b]pyridin-3-yl)methanol underwent oxidation to give compound II. All the invention compounds were evaluated for their protein kinase modulatory activity (some data given). The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Recommanded Product: 386704-04-7

The Article related to pyrrolopyridine preparation protein kinase modulator treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Recommanded Product: 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On January 4, 2007, Ibrahim, Prahbha N.; Artis, Dean R.; Bremer, Ryan; Mamo, Shumeye; Nespi, Marika; Zhang, Chao; Zhang, Jiazhong; Zhu, Yong-Liang; Tsai, James; Hirth, Klaus-Peter; Bollag, Gideon; Spevak, Wayne; Cho, Hanna; Gillette, Samuel J.; Wu, Guoxiam; Zhu, Hongyao; Shi, Shenghua published a patent.Reference of (6-(Trifluoromethyl)pyridin-3-yl)methanol The title of the patent was Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

Compounds of formula I which are active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. Compounds of formula I wherein Q is (un)substituted (hetero)aryl, and (un)substituted indole; A is O, S, (un)substituted methylene, NH and derivatives, CO, CS, SO and SO2; R4 – R6 are independently H, halo, (un)substituted lower alkyl, (un)substituted lower alkenyl, (un)substituted lower alkynyl, (un)substituted (hetero)cycloalkyl, (un)substituted (hetero)aryl, etc.; and their pharmaceutically acceptable salts, prodrugs, tautomer, and isomers thereof, are claimed. Example compound II was prepared by carboxylation of 2,4-difluoroaniline with benzyl chloroformate; the resulting benzyl 3-amino-2,6-difluorobenzoate underwent sulfonylation with propane-1-sulfonyl chloride to give benzyl 2,6-difluoro-3-(propylsulfonylamino)benzoate, which underwent hydrolysis to give the corresponding benzoic acid, which underwent chlorination and coupling with 5-bromo-7-azaindole to give compound II. All the invention compounds were evaluated for their protein kinase inhibitory activity. Several of the invention compounds exhibited good inhibitory activity against various protein kinases. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Reference of (6-(Trifluoromethyl)pyridin-3-yl)methanol

The Article related to pyrrolopyridine preparation protein kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Reference of (6-(Trifluoromethyl)pyridin-3-yl)methanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On January 19, 2012, Brown, Alan Daniel; Rawson, David James; Storer, Robert Ian; Swain, Nigel Alan published a patent.Recommanded Product: 386704-04-7 The title of the patent was Preparation of sulfonamide derivatives as Nav1.7 inhibitors. And the patent contained the following:

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors I [X = OCH2, CH2O; Het1 = (un)substituted 9-10 membered heteroaryl comprising 1-3 N atoms; R1 = (cyclo)alkyl (optionally substituted by 1-3 F atoms); R2-R4 = H, F, Cl or OMe; R5 = H, CN, F, Cl, etc.] which are potentially useful in the treatment of a wide range of disorders, particularly pain. Over sixty sulfonamides were prepared Thus, reacting 4-[(5-chloro-6-isobutoxypyridin-3-yloxy)methyl]-2,5-difluorobenzoic acid (preparation given) with methanesulfonamide afforded the sulfonamide II.HNEt2. Exemplified sulfonamides were tested for their ability to block the Nav1.7 channel (EIC50 values were provided). Pharmaceutical compositions comprising the title sulfonamide, alone or in combination with other therapeutic agent, were disclosed. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Recommanded Product: 386704-04-7

The Article related to sulfonamide benzamide preparation voltage gated sodium channel nav17 inhibitor, combination chemotherapy nav17 inhibitor sulfonamide amide benzamide preparation, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Amides, Amidines, Imidic Esters, Hydrazides, and Hydrazonic Esters and other aspects.Recommanded Product: 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On November 26, 2020, Buysse, Ann M.; Nugent, Benjamin M.; Gustafson, Gary D.; Meyer, Stacy T.; Loy, Brian A.; Kister, Jeremy; Gruber, Joseph M.; Jones, David M.; Avila-Adame, Cruz; Wang, Weiwei; Babij, Nicholas; Petkus, Jeff published a patent.SDS of cas: 386704-04-7 The title of the patent was Fungicidal aryl amidines and their preparation. And the patent contained the following:

This disclosure relates to aryl amidines of formula I and their use as fungicides. One embodiment of the disclosure is a use of a compound of formula I, for protection of a plant against attack by a phytopathogenic organism or the treatment of a plant infested by a phytopathogenic organism, comprising the application of a compound of formula I, or a composition comprising the compound to soil, a plant, a part of a plant, foliage, and/or roots. Compounds of formula I wherein R1 is H, (un)substituted C1-8 alkyl, (un)substituted C2-8 alkenyl, (un)substituted C2-8 alkynyl, etc.; R2, R3, R4 and R5 are independently H, halo, CN, NO2, etc.; R6 is H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, etc.; R6R7 may be taken together to form (un)substituted (un)saturated C1-8 heterocycloalkyl; R7 and R8 are independently H, (un)substituted C1-8 alkyl, (un)substituted C2-8 alkenyl, (un)substituted Ph, etc.; and tautomers thereof, are claimed. Example compound II was prepared by condensation of of 4-methylbenzyl 4-amino-2,5-dimethylbenzoate with N-(dimethoxymethyl)-N-methylethanamine. The invention compounds were evaluated for their fungicidal activity (data given). The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).SDS of cas: 386704-04-7

The Article related to aryl amidine preparation fungicide, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Amides, Amidines, Imidic Esters, Hydrazides, and Hydrazonic Esters and other aspects.SDS of cas: 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On January 4, 2007, Ibrahim, Prabha N.; Artis, Dean R.; Bremer, Ryan; Habets, Gaston; Mamo, Shumeye; Nespi, Marika; Zhang, Chao; Zhang, Jiazhong; Zhu, Yong-Liang; Zuckerman, Rebecca; West, Brian; Suzuki, Yoshihisa; Tsai, James; Hirth, Klaus-Peter; Bollag, Gideon; Spevak, Wayne; Cho, Hanna; Gillette, Samuel J.; Wu, Guoxian; Zhu, Hongyao; Shi, Shenghua published a patent.Formula: C7H6F3NO The title of the patent was Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

Compounds of formula I which are active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. Compounds of formula I wherein Q is (un)substituted aryl, (un)substituted indole, (un)substituted heteroaryl, etc.; A is O, S, (un)substituted methylene, NH and derivatives, CO, CS, SO and SO2; R4 – R6 is H, halo, (un)substituted lower alkyl, (un)substituted lower alkenyl, (un)substituted alkynyl, (un)substituted (hetero)cycloalkyl, and (un)substituted (hetero)aryl; and their pharmaceutically acceptable salts, prodrugs, tautomers, and isomers thereof, are claimed. Example compound II was prepared by carboxylation of 2,4-difluoroaniline with benzyl chloroformate; the resulting benzyl 3-amino-2,6-difluorobenzoate underwent sulfonylation with propane-1-sulfonyl chloride to give benzyl 2,6-difluoro-3-(propylsulfonylamino)benzoate, which underwent hydrogenation to give the corresponding benzoic acid, which underwent chlorination, to give the corresponding acid chloride, which underwent reaction with 5-bromo-7-azaindole to give compound II. All the invention compounds were evaluated for their protein kinase inhibitory activity. Several of the tested compounds exhibited good protein kinase inhibitory activity against several kinases. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Formula: C7H6F3NO

The Article related to pyrrolopyridine preparation protein kinase inhibitory activity, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Formula: C7H6F3NO

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On January 6, 2011, Guzzo, Peter R.; Surman, Matthew David; Grabowski, James Francis, Jr.; Freeman, Emily Elizabeth published a patent.Quality Control of (6-(Trifluoromethyl)pyridin-3-yl)methanol The title of the patent was Preparation of azinone-substituted azepinoindole derivatives as MCH-1 receptor antagonists and use in the treatment of diseases. And the patent contained the following:

Title compounds I [A = CH, C, or N; B = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; L = (CH2)pO, (CH2)p, CH=CH, or bond; X = CR18, C(R18)2, N, or NR18; Y = CR18, C, or N; Z = CH, C, or N; R1 = H, (un)substituted alkyl, cycloalkyl, heteroaryl, etc; R2 – R5 and R9 – R12 independently = H, halo, NH2 and derivatives, NHCO2H and derivatives, etc.; each R6 independently = H, halo, OH and derivatives, NH2 and derivatives, etc.; R7 = H, halo, NHCO2H and derivatives, (un)substituted aryl, heteroaryl, etc.; R8 = H, (un)substituted alkyl, cycloalkyl, heteroaryl, etc.; R13 and R14 independently = H, alkyl, haloalkyl, cycloalkyl, etc.; R18 = H, halo, NH2 and derivatives, (un)substituted alkyl, aryl, etc.; G = NR8CR9R10CR11R12, CR9R10NR8CR11R12, or CR9R10CR11R12NR8; provided that when G = CR9R10NR8CR11R12, R2 and R3 are not CONR13R14; n = 0 to 3; p = 1 to 4; dash bond represents an optional double bound], and their pharmaceutically acceptable salts, oxides, solvates, or prodrugs, are prepared and disclosed as MCH-1 receptor antagonists and useful in the treatment of obesity, anxiety, depression, non-alc. fatty liver disease, and psychiatric disorders. Thus, e.g., II·2HCl was prepared by cross-coupling of 2-bromo-5-trifluoromethylpyridine with 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine followed by demethylation, arylation with tert-Bu 8-bromo-6-methyl-1,2,4,5-tetrahydroazepino[4,5-b]indole-3(6H)-carboxylate, hydrolysis, and addition of hydrochloric acid. Select I were evaluated for their MCH-1 antagonistic activity, e.g., II·2HCl demonstrated a Ki value of 10.1 nM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Quality Control of (6-(Trifluoromethyl)pyridin-3-yl)methanol

The Article related to azinone azepinoindole derivative preparation mch receptor antagonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Quality Control of (6-(Trifluoromethyl)pyridin-3-yl)methanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On January 6, 2011, Guzzo, Peter R.; Surman, Matthew David; Henderson, Alan John; Hadden, Mark; Freeman, Emily Elizabeth published a patent.Product Details of 386704-04-7 The title of the patent was Preparation of (azabicycloalkyl)indole and (azabicycloalkyl)pyrrolopyridine derivatives as MCH-1 receptor antagonists and use in the treatment of diseases. And the patent contained the following:

Title compounds I [R1 = H, (un)substituted alkyl, cycloalkyl, heteroaryl, etc; D = NR2; R2 = H, (un)substituted alkyl, alkynyl, aryl, etc.; each R3 independently = H, halo, NH2 and derivatives, (un)substituted heteroaryl, etc; R4 = H, halo, NH2 and derivatives, (un)substituted alkyl, aryl, etc; A = (CH)n; B = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; L = (CH2)pO, (CH2)p, CH=CH, or bond; X = CR10, C(R10)2, N, or NR10; Y = CR10, C, or N; Z = CH, C, or N; R10 = H, halo, (un)substituted alkyl, cycloalkyl, heteroaryl, etc; m = 0 to 3; n = 1 or 2; p = 1 to 4; dash bond represents an optional double bound], and their pharmaceutically acceptable salts, oxides, solvates, or prodrugs, are prepared and disclosed as MCH-1 receptor antagonists and useful in the treatment of obesity, anxiety, depression, non-alc. fatty liver disease, and psychiatric disorders. Thus, e.g., II·2HCl was prepared by cross-coupling of 2-bromo-2-trifluoromethylpyridine with 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine followed by demethylation, arylation with tert-Bu 3-bromo-5-methyl-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole-11-carboxylate, hydrolysis, and addition of hydrochloric acid. Select I were evaluated for their MCH-1 antagonistic activity, e.g., II·2HCl demonstrated a Ki value of 6.5 nM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Product Details of 386704-04-7

The Article related to azabicycloalkane indole derivative preparation mch1 receptor antagonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Product Details of 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts